Givinostat, a histone‐deacetylase inhibitor that selectively targets JAK2V617F cell growth, seems to be a promising novel drug for PV.[77] Navitoclax (a novel anti‐apoptotic B‐cell leukaemia 2 [Bcl‐2] inhibitor), imetelstat (a telomerase inhibitor) and pelabresib (a BET inhibitor) might have disease‐modifying effects in patients with PMF.[78, 79, 80]. Here, BCL2 is linked to acquired polycythemia vera.